drugset / Trial / NCT01077453

Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer

NCT01077453 ↗

Phase 1 Completed 112 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupDouble-blindPrevention

Summary

This randomized phase I trial studies the side effects and the best dose of letrozole in preventing breast cancer in healthy postmenopausal women at high risk for breast cancer. Chemoprevention is the use of drugs to keep breast cancer from forming or coming back. The use of letrozole may keep cancer from forming in healthy postmenopausal women at high risk for breast cancer.

Timeline

Start
2010-03
Primary completion
2014-06
Completion
—

Outcome

Met primary endpoint

paper We conclude that low and intermittent doses of letrozole are not inferior to standard dose in estrogen suppression PMID 26667449 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 0.25 mg Oral
Subject Letrozole Other / unclassified 1 mg Oral
Subject Letrozole Other / unclassified 2.5 mg Oral